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slightly higher disease burden and comorbidities. Factors influencing the observed 
patterns (including the choice of specific biologic for targeted patient profiles) may 
warrant further scrutiny to optimize therapeutic interventions and improve out-
comes.
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ASSeSSMent of the QuAlity of life in ChineSe MyAStheniA GrAviS 
PAtientS
Zhang H.Y., Xie W.F., Zhang J.S., Yang G.L.
Liaoning University of Traditional Chinese Medicine, Shenyang, China
OBJECTIVES: Myasthenia Gravis (MG) is an auto immune disease of neuromuscular 
junction, which influences patients’ quality of life (QoL). Studies had showed MG 
patients with poor QoL, but there is no data in Chinese MG patients. METHODS: 
Consecutive MG patients are enrolled in three hospitals in Shenyang, China, from 
July, 2008 to June, 2010. Patients (14≤ age≤ 75 years) with class ‡T, ‡Ua, or ‡Ub MG 
according to Osserman’s classification are enrolled, and are separated into Ocular, 
Mild and Moderate groups. Familial MG, congenital MG and drug-induced MG 
are excluded. QoL is assessed by the SF-36 (rang: 0-100); severity of the disease is 
assessed by Chinese Score for MG (CSMG rang 12-60; higher scores worse weakness). 
Differences are tested using ANOVA and Kruskall-Wallis as appropriate. RESULTS: 
Analysis is based on 248 patients (male 110, 44%; age:46±18 year), of whom 27%, 
35% and 38% classified into Ocular, Mild and Moderated groups respectively. The 
disease history is 47±64 months (median 24). Fifty-nine patients have at least one 
comorbidity, and 71 with thymic hyperplasia, and 49 thymectomy. There is no sig-
nificant difference in demographic characteristics among three groups (P> 0.05), and 
no difference in disease history, comorbidity and treatment either. Ocular group has 
better QoL than Mild and Moderated groups: 64, 57, 51 for each group respectively 
(P= 0.000), and better weakness in CSMG scores: 21, 23, 26 respectively (P= 0.000). 
Significant differences is found in all the subscales of SF-36 among groups (P< 0.05), 
except for general health (P= 0.054), social functioning (P= 0.490), and role-emotional 
(P= 0.104). CONCLUSIONS: Our study reveals that Chinese MG patients have poor 
QoL, and Ocular MG patients have better QoL than those who are Mild and Moderate 
MG, and QoL is influence by the degree of muscle weakness.
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OBJECTIVES: Previous clinical trials have demonstrated that gout patients who 
achieve the target serum urate acid (SUA) level ≤ 6 mg/dL with urate lowering ther-
apy (ULT) experience a reduction in the frequency of gout flares over time. This find-
ing has not been fully exploited in pharmacoeconomic models of ULTs that associate 
constant flare rates with SUA levels. The objective of this study was to quantify the 
long-term rate of decrease in flare frequency among subjects who achieved the tar-
get SUA level in the fEbuXostat/allopurinol Comparative Extension Long-term study 
(EXCEL). METHODS: The EXCEL trial reported the proportion of subjects experienc-
ing ≥ 1 gout flare requiring treatment by two-month intervals. Binomial regression 
was used to fit Gompertz and Weibull survival models to the observations at least 
6 months after baseline, pooled across treatment arms. Model fit was assessed 
by a chi-square test of the model deviance. RESULTS: The goodness of fit test for 
the Gompertz survival model indicated that the model provides an adequate fit to 
the data (model deviance = 14.14 with 15 degrees of freedom; p= .5146). However, 
the goodness of fit test for the Weibull survival model indicated an inadequate 
fit to the data (model deviance = 55.01 with 15 degrees of freedom; p< .0001). The 
maximum likelihood estimate of the shape parameter of the Gompertz survival 
model is -0.0906, where time is measured in months. CONCLUSIONS: The long-
term (≥ 6 months after baseline) gout flare results reported in the EXCEL trial can 
be adequately modeled by a Gompertz survival model, which estimates that the 
gout flare rate decreased by 9.06% per month for subjects who achieved the target 
SUA level of ≤ 6 mg/dL. The results of this analysis may be useful for modeling the 
long-term clinical and economic outcomes of ULTs in patients with gout.
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OBJECTIVES: Evidence supporting the use of anti-osteoporosis (AO) medications 
(AOMs) for preventing fracture among elderly patients with end-stage renal disease 
(ESRD) was scarce. This study evaluated the benefits of AOMs in fracture preven-
tion for elderly patients with ESRD. METHODS: Using 1997-2008 Taiwan’s National 
Health Insurance research database, we identified incident chronic dialysis patients 
with concomitant diagnosis of osteoporosis who had received AOMs during the 
year before dialysis between 1998 and 2007; the AOMs included salmon calcitonin, 
alendronate, zoledronate, raloxifene, and teriparatide. Following the inception of 
dialysis, patients who continued AOMs were categorized into AO treated cohort 
and those who ceased using AOMs were AO untreated cohort. Study outcomes were 
defined as hospitalizations due to hip or vertebral fracture during the follow-up 
period. RESULTS: We identified 490 patients receiving AOMs during the year before 
dialysis. The mean age of AO untreated cohort and AO treated cohort were 74.40 and 
71.64. Fracture hazard risk (HR) in the AO treated cohort was not significantly lower 
than the AO untreated cohort, either unadjusted (HR = 1.02, 95%CI = 0.40-2.62, p = 
0.96) or adjusted (HR = 0.92, 95%CI = 0.30-2.82, p = 0.89). Further analysis in female 
patients resulted in a similar finding. CONCLUSIONS: This study found that use 
of AOMs was not associated with a reduction of fracture risk in elderly chronically 
dialyzed patients.
retrospective medical chart-review of RA patients was conducted to collect de-
identified data for those recently treated with a biologic as part of usual care. 
Physicians (rheumatologists) were screened for duration of practice (3-30yrs) and 
patient volume (incl. > 5 RA biologic patients/month) and recruited from a large 
panel to be geographically representative. Eligible patient charts (≥ 3) were randomly 
selected from a sample of patients visiting each center/practice during the screen-
ing period. Physicians abstracted patient diagnosis, treatment patterns/dynamics 
and patient symptomatology/disease status/outcomes. Patients on adalimumab/
etanercept monotherapy were analyzed. RESULTS: 169 eligible RA patient charts 
were abstracted; 43 on adalimumab (female: 63%, age: 51.7 yrs, average months on 
adalimumab: 39.5, 98% on first biologic) and 63 on etanercept (female: 78%, age: 49.3 
yrs, average months on etanercept: 40.2, 87% on first biologic). Top-3 comorbidites 
(adalimumab vs. etanercept) were obesity: 21% vs. 10%, dyslipidemia: 21% vs. 6% 
and depression/anxiety: 12% vs. 11%. Among patients with available data, latest lab 
measures documented were (adalimumab vs. etanercept): ESR: 26.4 mm/h vs. 23.4 
mm/h, CRP: 2.6 mg/dl vs. 1.7 mg/dl, rheumatoid factor-positive: 84% vs. 73%, and 
anti-CPP-positive: 65% vs. 59%. Latest disease severity measures documented were 
(adalimumab vs. etanercept): Swollen Joint Counts: 1.7 vs. 1.6, Tender Joint Counts: 
2.5 vs. 2.8, and VAS score: 2.4 vs. 2.2. CONCLUSIONS: RA patients on adalimumab 
monotherapy were slightly older and had a lower percentage of female patients than 
those on etanercept. Most (> 85%) were on their first biologic. The adalimumab group 
appeared to have a slightly higher disease burden and comorbidities. Factors influ-
encing the observed patterns (including the choice of specific biologic for targeted 
patient profiles) may warrant further scrutiny to optimize therapeutic interventions 
and improve outcomes.
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OBJECTIVES: Tofacitinib is a new oral drug which has demonstrated efficacy and 
safety in pivotal clinical trials. This study sough to assess the efficacy of tofaci-
tinib in combination with methotrexate compared with biological DMARDs in 
combination with methotrexate, in rheumatoid arthritis (RA) patients with an 
inadequate response to methotrexate. METHODS: We performed an analysis of 
systematic review published in the last five years that assessed biological DMARDs 
(Adalimumab, certolizumab, infliximab, etanercept, golimumab, tocilizumab, rituxi-
mab and abatacept) or tofacitinib to treatment of RA after inadequate response 
to methotrexate. The search was realized in the database of Medline, EMBASE, 
Cochrane, LILACS, DARE and HTA. The data collection was realized by two research-
ers independently. Clinical trials that had been included in the systematic reviews 
were extracted and evaluated their methodological quality with checklist Cochrane. 
With mixed treatment comparison, the effectiveness between biological DMARDs 
and tofacitinib was compared using methotrexate as a common comparator. The 
outcomes considered in terms of effectiveness were improvement rates by ACR20, 
ACR50, ACR70 and HAQ criteria at 12 and 24 weeks. In order to evaluate the impact 
of heterogeneity, we performed analysis of sensibility and subgroups. RESULTS: 
27 systematic reviews were included of which 30 clinical trials were assessed and 
analyzed. The indirect comparison showed that tofacitinib has similar efficacy in 
comparison to biological DMARDs in ACR20, ACR50, ACR70 and HAQ at 12 and 24 
weeks. However, certolizumab displayed better response that tofacitinib in ACR20 
at 12 weeks (OR 0.373 IC 95% 0.201 – 0.615). The sensitivity and subgroup analyses 
by the design of clinical trials, years of disease and number of swollen joint showed 
consistent results. CONCLUSIONS: The mixed treatment comparison indicated that 
tofacitinib is similar in terms of efficacy than biological DMARDs in RA patients with 
an inadequate response to methotrexate.
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OBJECTIVES: To compare the disease status and outcomes of patients with PsA 
receiving adalimumab and etanercept monotherapy in the US. METHODS: A retro-
spective medical chart-review of PsA patients was conducted to collect de-identified 
data for those recently treated with a biologic as part of usual care. Physicians 
(rheumatologists) were screened for duration of practice (3-30yrs) and patient 
volume (incl. > 5 PsA biologic patients/month) and recruited from a large panel 
to be geographically representative. Eligible patient charts (≥ 3) were randomly 
selected from a sample of patients visiting each center/practice during the screen-
ing period. Physicians abstracted patient diagnosis, treatment patterns/dynamics 
and patient symptomatology/disease status/outcomes. Patients on adalimumab/
etanercept monotherapy were analyzed. RESULTS: 84 eligible PsA patient charts 
were abstracted; 37 on adalimumab (male: 54%, age: 46.5 yrs, average months on 
adalimumab: 28.2, 92% on first biologic) and 29 on etanercept (male: 62%, age: 42.3 
yrs, average months on etanercept: 32.2, 100% on first biologic). Top-5 comorbid-
ites (adalimumab vs. etanercept) were obesity: 24% vs. 17%, dyslipidemia: 8% vs. 
7%, diabetes: 8% vs. 3%, kidney disease: 8% vs. 0%, migraine: 3% vs. 3%. Among 
patients with available data, latest lab measures documented were (adalimumab 
vs. etanercept): ESR: 28.0 mm/h vs. 15.8 mm/h and CRP: 3.9 mg/dl vs. 2.3 mg/dl. 
Latest disease severity measures documented were (adalimumab vs. etanercept): 
Swollen Joint Counts: 1.8 vs. 1.1, Tender Joint Counts: 2.6 vs. 3.9, and HAQ rating: 0.7 
vs. 0.3. CONCLUSIONS: PsA patients on adalimumab monotherapy were slightly 
older and on adalimumab for fewer average months than patients on etanercept. 
Most (> 90%) were on their first biologic. The adalimumab group appeared to have a 
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1540.59 days). CONCLUSIONS: Higher age and having arthroplasty were associated 
with increased risk of secondary hip fracture in elderly women. The higher risk of 
secondary hip fracture in patients with hip arthroplasty could be explained by their 
longer survival after primary treatment. Further analyses of risk factors are needed 
to elaborate effective prevention strategies for secondary hip fractures.
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OBJECTIVES: Bone loss is a common problem occurring among human immunode-
ficiency virus (HIV)-positive patients. Explanations for the bone loss are unknown. 
We estimated the prevalence of osteopenia among HIV-positive adults ages 18-49 
versus matched HIV-negative adults; and ranked predictors for osteopenia in terms 
of their contribution to a prediction model. METHODS: We conducted a cross-sec-
tional study on the 2005-2010 National Health and Nutrition Examination Survey 
(NHANES). HIV-positive individuals were identified according to HIV antibody test. 
Bone mineral density (BMD) T-score of femur neck was calculated based on the mean 
and SD from data for non-Hispanic white females ages 20-29 from the NHANES III. 
Osteopenia was defined as T-score between -1 and -2.5; osteoporosis was defined 
as T-score less than -2.5. A HIV-positive adult was matched with 3 HIV-negative 
adults at the same sex, age category and race. We used multiple logistic regression 
identified predictors of osteopenia among the matched cohort. RESULTS: 52 HIV-
positive individuals were identified. In the matched cohort 46 HIV-positive and 
138 HIV-negative adults were included. The mean age of the matched cohort was 
39.3±9.0 years, and 76.1% were male. No osteoporosis was observed in either case 
group or control group. The prevalence of osteopenia was 7.3% versus 1.7% among 
the cases compared to controls. Osteopenia occurred only among males in the cases 
and females in the controls. Alcohol consumption (p< 0.0001) was the strongest 
predictor of osteopenia, followed by activity intensity (p= 0.0003), family history of 
osteoporosis (p= 0.0007), and HIV itself (p= 0.0026), after controlling BMI and smoking 
status. CONCLUSIONS: HIV itself is a significant predictor for osteopenia; but due 
to lack of information on treatment history, it remains unclear if HIV medicine or 
treatment duration can increase the risk of osteopenia.
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OBJECTIVES: The risk of subsequent hip fracture is increased in presence of previous 
hip fracture. The most of the secondary hip fractures occur within the first 3 years 
after the initial hip fracture. The aim of our nationwide retrospective observational 
cohort study was to reveal the significance of demographic and clinical factors on 
time until subsequent hip fracture. METHODS: Patients aged 60 and over treated 
with primary femoral neck fractures in the year 2000 and suffered from contralateral 
hip fracture between 01 January 2000 and 31 December 2008 were selected from the 
database of the Hungarian National Health Insurance Fund. Patients’ data concern-
ing their age, gender, place of living, type of primary fracture, comorbid medical 
diseases, surgical intervention for primary fracture and hospital providing treatment 
for primary hip fracture were evaluated. Multinominal logistic regression were used 
to analyse associations between prognostic factors and the time (< 12 months, 12-24 
months, 24-36 months, 36-48 months, 48-60 months, > 60 months) until secondary 
fracture. RESULTS: 312 patients met the criteria. Having osteosynthesis as surgical 
intervention for primary fracture (osteosynthesis vs. arthroplsty, HR: 6.11, p= 0.02, 
CI: 1.28- 29.17) was significantly associated with a greater likelihood of suffering 
from secondary fracture in the fifth year than in the first year. Patients between 
60 and 69 years (60-69 years vs. > 90 years, HR: 20.95, p= 0.010, CI: 2.09- 209.44) were 
significantly more likely to have contralateral fracture in the sixth year than in the 
first year. CONCLUSIONS: First, we provide evidence of the influence of higher 
age and osteosynthesis as surgical intervention for primary fracture on the time 
until subsequent hip fractures in elderly Hungarian population. The results may 
help establish an effective strategy for the prevention of secondary hip fractures.
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OBJECTIVES: Approximately 10% of the US population is diagnosed with knee 
osteoarthritis by age 60. Disability due to arthritis increases health care costs and 
the risk of hospitalization, institutionalization, and mortality. Decreasing seden-
tary behavior can improve function and may be a modality for improving quality 
adjusted life years (QALYs). The purpose of this study was to investigate whether 
varying levels of sedentary behavior impacts the QALY differently. METHODS: This 
study used longitudinal data from the accelerometer study of the Osteoarthritis 
Initiative (OAI) collected at baseline (OAI 48-month visit) and 2-year follow-up 
(OAI 72-month visit). We restricted analyses to participants with 4-7 valid days 
of accelerometer monitoring and individuals with complete health utility data, 
yielding a sample of 1794 community dwelling adults with or at risk for radio-
graphic knee OA. QALYs (SF6D) were calculated at 48 and 72 months. Participants 
were classified into quartiles based on average daily sedentary time (most seden-
tary Q1 > = 11.6, 10.7< = Q2< 11.6, 9.7< = Q3< 10.7, least sedentary Q4< 9.7 hours). The 
association between sedentary behavior and QALYs was examined using median 
regression adjusting for age, gender, BMI. RESULTS: Average(SD) QALYs over the 
2-year follow-up were 1.56(0.23), 1.61(0.20), 1.60(0.23), 1.60(0.23) for Q1-Q4 respec-
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OBJECTIVES: Limited information exists on real-world use of biologic agents in 
ankylosing spondylitis (AS). This study evaluated the treatment patterns and costs 
of biologic therapy and disease-modifying antirheumatic drugs (DMARDs) in AS 
patients. METHODS: MarketScan claims databases were used to identify biolog-
ics treatment-naïve AS patients (≥ 18 years of age with no biologics in the past 
6 months) who initiated biologic treatment between 10/1/2009 and 09/30/2010. 
Frequency of biologic switching, duration, modification of treatment, and medical 
and pharmacy drug costs for each line of biologic therapy was analyzed during the 
3-year follow-up. RESULTS: A cohort of 339 AS patients was identified. First-line bio-
logics were: etanercept (n= 140), adalimumab (n= 137), infliximab (n= 41), golimumab 
(n= 18) and certolizumab pegol (n= 3). Approximately two-thirds of the patients 
(64.6%) discontinued their first-line biologic therapy and did not restart any biologi-
cal therapy, 23.6% of patients stayed on their first-line, 8.8% switched to second-line 
and 2.9% to third-line therapies. Patients who switched to a second- or third-line 
biologic treatment remained on their first-line agent for less time (336, 325-days, 
respectively) than those who did not switch (502-days). Most common treatment 
modifications in first-line were DMARD add-on (6.5%) and removal (5.6%). Time to 
first treatment-modification was shorter for those who switched to second- (88 
days) and third-line therapy (6-days) vs. those who remained on first-line (160-days). 
Monthly-per-member medical costs were greatest for non-switchers ($363) than for 
patients who received second-($249) or third-line ($113) treatment. Monthly-per-
member overall pharmacy drug costs were similar for patients with first-($1,908), 
second-($1,955) or third-line and above ($1,890) therapy. CONCLUSIONS: Sixty 
five percent of AS patients discontinued their first-line agent during the follow-up 
period. Those who switched biologics had more modifications to their treatment. 
Patients who switched to second- or third-line biologics had lower medical costs; 
however, their pharmacy costs were similar to those who continued their first-line.
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OBJECTIVES: Information is limited regarding the interim and long-term outcomes 
associated with knee microfracture surgery. The objective of the study was to describe 
failure rates 1 year, 3 years, and 5 years after knee microfracture surgery in an admin-
istrative claims database. METHODS: Beneficiaries with knee microfracture surgery 
between 10/1/2007 and 9/30/2008 (index surgery) and continuous enrollment 24 
months prior to the index surgery were identified in the Truven Health Marketscan® 
Commercial, Medicare Supplemental, and Medicaid databases. Patients with any knee 
procedures in the 2 years prior to index surgery were excluded. Patients were fol-
lowed for a minimum of 3 years after the index surgery and a subgroup of patients 
were followed for 5 years. Procedure failure was defined as receiving a total knee 
replacement (TKR) or revision, microfracture or autologous chondrocyte implantation 
subsequent to index surgery. RESULTS: A total of 3,498 patients (2,948 commercial 
payer, 351 Medicare and 199 Medicaid) met the study inclusion criteria. Failure rates 
increased with increasing years of follow-up: 9% within 1 year, 18% within 3 years, 
and 32% within 5 years. Among commercial payer patients, 8% were failures after 
1 year, compared to 16% after 3 years and 31% after 5 years. The highest rates of 
failure were observed among Medicare beneficiaries, in which 18%, 30%, and 41% of 
patients received knee procedures within 1 year, 3 years, and 5 years, respectively. 
Failure rates defined by TKR after microfracture surgery were 5% within 1 year, 12% 
within 3 years, and 22% within 5 years. CONCLUSIONS: Although the gold standard, 
knee microfracture surgeries have high failure rates as defined by repeat procedures 
within five years. There is a need for procedures that provide durable improvements 
in health outcomes and reduce the need for repeat interventions.
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OBJECTIVES: Hip fracture is most serious consequence of osteoporosis with sig-
nificant financial and personal costs. Our aim was to determine the significance 
of demographic and clinical factors for contralateral hip fracture among elderly 
women. METHODS: In our retrospective observational cohort study women aged 
60 years and over treated with primary femoral neck fractures in the year 2000 
were selected from the database of the Hungarian National Health Insurance Fund. 
Contralateral hip fractures were recorded between 01 January 2000 and 31 December 
2008. Patients’ data including age, place of living, hospital providing treatment for 
primary hip fracture, type of primary fracture, comorbidities, type of primary surgi-
cal intervention and survival time were studied. Prognostic factors of secondary hip 
fracture were evaluated using multivariate Cox proportional hazard regression and 
Kaplan-Meier survival analysis. RESULTS: 2866 subjects met the criteria. 263 patients 
(9.17%) suffered from secondary hip fracture during the observation period. The mean 
time until secondary fracture was 1142.82 days. Expressed as cases per person-years 
the incidence of subsequent hip fracture was 0.23. Significant correlations were found 
between higher age (years, HR: 1.03, p< 0.001, CI: 1.01- 1.05), having hip arthroplasty 
as type of surgical intervention for primary fracture (osteosynthesis vs. arthropl-
sty, HR: 1.63, p= 0.022, CI: 1.19- 2.24) and occurrence of subsequent hip fractures. 
Comparing patients’ survival on different surgical intervention, log rank test showed 
significantly longer survival (p= 0.027) in patients with arthroplasty (mean survival 
time: 1739.84 days) compared with those having osteosynthesis (mean survival time: 
